By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioMarin Pharmaceutical Inc. 

105 Digital Drive

Novato  California  94949  U.S.A.
Phone: 415-506-6700 Fax: 415-382-7427


BioMarin leads the biotechnology industry in delivering therapies for chronic and degenerative genetic conditions that reduce patients' quality of life and shorten life spans. We target diseases that lack effective therapies and affect relatively small numbers of patients, many of whom are children. BioMarin continues to focus on advancing therapies that are the first or best of their kind and make a big difference in improving patients' lives.

BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.

BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates.

You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.

Key Statistics

Ownership: Public

Web Site: BioMarin
Employees: 358
Symbol: BMRN

Company News
Evaluation: 7 Biopharma Companies’ Market Value Based on Pipelines 7/14/2016 6:31:45 AM
4 High-Quality Biotechs Trading Like Risky Startups 7/11/2016 6:45:50 AM
BioMarin (BMRN) Shoots Up on Roche (RHHBY) Takeover Rumor 7/7/2016 10:32:30 AM
If Spurned By Medivation (MDVN), Sanofi (SNY) May Turn to BioMarin (BMRN) for a Little Love 6/17/2016 7:03:01 AM
BioMarin (BMRN) Stock Wobbles After Hemophilia A Trial Suspended 6/17/2016 7:00:51 AM
All Eyes Turn to Sarepta (SRPT) as BioMarin (BMRN) Shutters Its Kyndrisa Duchenne Program 6/1/2016 6:25:05 AM
Nine Bay Area Biotechs Vie to be the “Next Genentech (RHHBY)” 5/24/2016 6:33:42 AM
BioMarin (BMRN) To Host First Quarter 2016 Financial Results Conference Call And Webcast On Thursday, April 28 At 4:30pm ET 4/12/2016 8:03:39 AM
3 Depressed Biotechs that Investors with a Long-Term Perspective Should Buy Right Now 4/11/2016 6:36:51 AM
PSI And BioMarin (BMRN) Named Finalists For 2016 Pharmatimes Strategic Partnership Competition 4/5/2016 8:34:49 AM